Eli Lilly will use a priority review voucher on Mounjaro to 'remove any uncertainty' around fast FDA review

Nicole DeFeudis

Editor

Eli Lilly isn’t waiting around for the FDA’s fast-track pathway. The team is “feverishly” submitting its new Phase III data for Mounjaro in obesity, and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Eli Lilly will use a priority review voucher on Mounjaro to 'remove any uncertainty' around fast FDA review

Nicole DeFeudis

Editor

Sign up to read this article for free.

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Eli Lil­ly will use a pri­or­i­ty re­view vouch­er on Moun­jaro to 're­move any un­cer­tain­ty' around fast FDA re­view

Nicole DeFeudis

Editor

Sign up to read this article for free.

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

FDA says Ozem­pic, We­govy short­age is over

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Eli Lilly will use a priority review voucher on Mounjaro to 'remove any uncertainty' around fast FDA review

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence